HIV Vaccine Awareness Day 2023: Hard lessons, innovation & new directions

May 18th is recognized as HIV Vaccine Awareness Day (HVAD), and this year it is a time of deep reflection and potential. Three major HIV vaccine trials have ended in no efficacy since 2020, but the field knows more than ever that a vaccine is still needed for a durable and sustainable end to the pandemic – and has new insights into possible vaccine strategies that might one day effectively protect against HIV.

This year, AVAC and CASPR partners are casting a spotlight on the many issues and opportunities for HVAD 2023. Check it all out here! And read on for details about a wide range of new resources.

New PxPulse Podcast Episode!

billboard advertising the new podcast episode

Listen to the newest PxPulse podcast, “Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why,” featuring Katy Stephenson of Harvard Medical School, Beth Israel Deaconess Medical Center, and the Center for Virology and Vaccine Research. In conversation with AVAC’s Jeanne Baron, Katy provides an accessible breakdown of where the field of HIV vaccine research is, including details on recent trial results that proved ineffective and what’s next (and exciting) in HIV vaccine advocacy and research.

Save the Date for Two Upcoming Webinars!

save the date advertisement for these upcoming webinars

What’s All the Buzz About: mRNA, manufacturing, vaccines access

Thursday, June 1 at 10am ET / 4pm SAST
Featuring Caryn Fenner of Afrigen Biologics, Ike James of Medicines Patent Pool, and Mike Frick of Treatment Action Group. Register here.

To bNAb or not to bNAb? The case for broadly neutralizing antibodies

Wednesday, June 7 at 10 AM ET / 4 PM SAST
Featuring Slim Abdool Karim of CAPRISA, Pervin Anklesaria of Bill & Melinda Gates Foundation, Khadija Richards of Wits RHI, and Huub Gelderblom of HIV Vaccine Trials Network (HVTN). Register here.

CASPR Partner and Collaborator HVAD Events

Communities across the globe will be engaged in a wide array of events focused on HIV vaccine awareness in the coming days. Here, we provide details on activities the Coalition to Accelerate & Support Prevention Research (CASPR) partners are leading – be sure to watch AVAC’s Twitter for real-time highlights!

New Series of Advocate Briefs

screenshot of the header of this document

In the weeks to come, we’ll release From the Lab to the Jab, a series of briefs on next generation vaccine research and development; the basics of mRNA technology; initiatives that support local manufacturing; and understanding and overcoming barriers that undermine equitable access to vaccines. Each brief also highlights the advocacy needed to keep these efforts on track and in line with what communities need and want.

New Resources

AVAC has updated our recent HIV vaccine primers. And we’re sharing a viewpoint written in the Journal of the International AIDS Society.

As the science continues to advance, we hope these resources inform our collective advocacy. With the knowledgeable voices of advocates guiding the response, scientific successes will not be squandered, communities won’t be left behind, programs will be people-centered, and epidemics will end.

Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?

Produced and hosted by Jeanne Baron

With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there’s no clear concept that’s ready to test in a late-phase trial or move towards product development currently. Researchers are back to testing new ideas in early phase research.

In this episode of our Px Pulse podcast, Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?, Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. Katy is a doctor, a researcher, a professor of medicine at Harvard Medical School, affiliated with Beth Israel Deaconess Medical Center, and part of the Center for Virology and Vaccine Research.

Listen:

Resources:

Experimental Medicine Vaccine Trials (EMVTs): Opportunities and Challenges

In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.

Avac Event

IAS (International AIDS Society) 2023

The 12th annual conference of the International AIDS Society (IAS) on HIV science takes place July 23–26 in Brisbane, Australia, and virtually. This year’s conference will offer the latest on vaccine and cure science, research updates on broadly neutralizing antibodies, important discussions on trial design in the era of PrEP, the potential of community-led models of care and the importance of integrating services for HIV and sexual and reproductive health (SRH). AVAC and partners will be there! Read on for an overview.

Just ahead of the conference, UNAIDS released their annual state of the epidemic report, The Path that Ends AIDS. The report charts a path that can end AIDS, and documents important progress, but challenges remain. Among them, global resources for HIV are marking another year of decline. With anti-LGTBQIA+ legal actions increasing in the US and in several African countries and reduced resources, efforts to end the epidemic will fail. See AVAC’s new graphic on the issue.

IAS Resources

  • Use AVAC’s Roadmap to find sessions where prevention, pandemic preparedness and the larger issues of global health equity are in the spotlight. You can download it as a sortable spreadsheet or PDF.
  • Follow events in real time, AVAC will offer comments and updates on Twitter, and our friends at NAM/AIDSMAP will be reporting throughout the conference. Join the conversation using the conference hashtag #IAS2023.

Satellites, Sessions and Panels Featuring AVAC and Partners

All times listed are local in Brisbane, Australia. Click for a time zone converter.

Sunday, July 23

Tuesday, July 25

Wednesday, July 26

Poster Presentations

  • No Data No More: A tool to end the exclusion of trans and gender-diverse people in HIV research
  • Raising New Voices in HIV Cure Research: A review of an advocacy-for-cure academy and grant program
  • The Value of Measuring Outcomes of HIV Advocacy: Utilising a novel and participatory approach for advocacy evaluation
  • HIV Prevention Research & Development Investments 2001-2021: Shifting investment priorities fund innovation in a challenging global health landscape
  • Revolution of Transgender Health Programming: The role of transgender activists in Health programming for Malawi

While many will be gathering in Australia for the IAS conference, the 27th International Society for Sexually Transmitted Diseases Research (ISSTDR)is happening in Chicago at the same time – and AVAC will be there, too. Stay tuned for an update later this week for AVAC’s STI Roadmap and dedicated STI conference page. Advocates, implementers and researchers in both fields have much work to do together.

hivresourcetracking.org

The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.

In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.

Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials

Current trends for investment in HIV prevention R&D by technology

Status Updates on Ongoing and Planned HIV Prevention Trials

The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.

How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.

AIDS Vaccines by the Numbers: Trials, discoveries, money and more

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

HIV Vaccines: An introductory factsheet

This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.